erythro-Austrobailignan-6_product_DataBase

Bioactivity	erythro-Austrobailignan-6 is an orally active anti-cancer agent. erythro-Austrobailignan-6 inhibits DNA topoisomerase I and II activity. erythro-Austrobailignan-6 induces cell apoptosis and increases phosphorylation of p38 and JNK[1][2].
Invitro	erythro-Austrobailignan-6 (100 μM) 抑制 DNA 拓扑异构酶 I 活性超过 50%[1]。erythro-Austrobailignan-6 (0-30 μM, 24 或 48 h) 抑制 4T-1 细胞和 MCF-7 细胞的增殖[1].erythro-Austrobailignan-6 (2-30 μM，24 或 48 小时) 诱导 4T-1 和 MCF-7 细胞凋亡[1]。erythro-Austrobailignan-6 (10 μM，30-120 分钟) 增加4T-1 和 MCF-7 细胞 p38 和 JNK 的磷酸化水平[1]。erythro-Austrobailignan-6 (5 和 10 μM，24 小时) 降低 4T-1 和 MCF-7 细胞中的 EGFR/HER2 和拓扑异构酶水平[1]。 Cell Viability Assay[1] Cell Line:
Name	erythro-Austrobailignan-6
CAS	114127-24-1
Formula	C20H24O4
Molar Mass	328.40
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

PeptideDB